Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Quantitative Fundus Autofluorescence (qAF) is defined as an advanced imaging technique that measures the absolute intensity of the retina's natural "glow" to map the accumulation of lipofuscin. Unlike standard FAF: qAF provides:
Lipofuscin is a metabolic "waste product" that builds up in the Retinal Pigment Epithelium (RPE). While a small amount is normal: excessive accumulation is a hallmark of:
Standard FAF gives a "picture" that shows light and dark areas; but the brightness depends on the camera settings. qAF uses a calibrated internal "reference" so that the brightness values are absolute. This means a scan taken today can be mathematically compared to a scan taken three years from now to see exactly how much the disease has progressed.
The patient sits at a specialized scanning laser ophthalmoscope (SLO). A blue or green light is used to "excite" the retinal pigments. The camera then captures the emitted light. The process is non-invasive: requires no injections (unlike fluorescein angiography): and usually takes less than five minutes per eye after dilation.
Yes: qAF is a primary tool in clinical trials for new retinal drugs. Because it provides a "number" for retinal health: it allows researchers to prove whether a new treatment is successfully slowing down the accumulation of toxic waste products in the eye; making it a vital "biomarker" for modern medicine.
The light used for qAF is bright: but it is not painful. Some patients may experience a "bleached" sensation or see spots for a few minutes after the test; similar to the effect of a camera flash. This is temporary and does not cause any permanent damage to the retinal cells.
They show different things. An OCT shows the "structure" (the layers of the eye); while qAF shows the "metabolic health" (how the cells are functioning). Doctors often use both tests together to get a complete 3D and functional map of the patient's visual system.
In many cases; yes. By tracking the rate of lipofuscin accumulation; doctors can often predict where geographic atrophy (cell death) will occur next. This allows for earlier lifestyle interventions or more frequent monitoring to protect the patient's remaining central vision.